Product
Zepbound (tirzepatide)
Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Self-pay $299 to $449/month via…
$299/mo
Mounjaro (tirzepatide)
Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for type 2 diabetes. Not approved for weight management. Official self-pay price not publicly verified (Sept 20, 2026).
At a glance
Self-pay from
Not verified
no official price confirmed yet
How it is taken
Subcutaneous injection, once weekly
FDA status
FDA-approved
Not approved for weight management
Data last checked
September 20, 2026
Needs review
FDA-approved for
- Type 2 diabetes (see Prescribing Information for full indications)
Self-pay price by dose
We have not verified a current price yet
Could not be independently verified from an official Lilly source (checked Sept 20, 2026)
We only list a price once we can confirm it from an official source. Ask the pharmacy for a quote for your prescribed dose.
How the price compares
Lowest standard self-pay price per month from each manufacturer’s own pharmacy. Introductory offers and insurance prices are excluded. Medications, doses and approved uses differ, so this is a price reference, not a treatment comparison.
Key facts
- Medication class
- Dual GIP and GLP-1 receptor agonist
- Active ingredient
- Tirzepatide
- Manufacturer
- Eli Lilly and Company
- Prescription required
- Yes
About this medication
Mounjaro is a once-weekly tirzepatide injection from Eli Lilly, FDA-approved for type 2 diabetes. It is not FDA-approved for chronic weight management; Zepbound is the tirzepatide product approved for that use.
We could not independently verify a current Mounjaro self-pay price on Eli Lilly’s public pages as of September 20, 2026. Some third-party sites report a LillyDirect price, but we do not list a price until we can confirm it from an official source. Ask the pharmacy for a quote for your prescribed dose.